Skip to main content
Top
Published in: Rheumatology International 4/2013

01-04-2013 | Original Article

Late appearance and exacerbation of primary Raynaud’s phenomenon attacks can predict future development of connective tissue disease: a retrospective chart review of 3,035 patients

Authors: Slavica Pavlov-Dolijanovic, Nemanja S. Damjanov, Nada Z. Vujasinovic Stupar, Goran L. Radunovic, Roksanda M. Stojanovic, Dragan Babic

Published in: Rheumatology International | Issue 4/2013

Login to get access

Abstract

To assess the prognostic value of the age at onset of Raynaud’s (RP) and of a history of exacerbation of RP attacks for the development of connective tissue disease (CTD) in patients initially found to have primary Raynaud’s. 3,035 patients with primary RP (2,702 women and 333 men) were followed for an average of 4.8 years (range from 1 to 10 years). At baseline and every 6 months, they were screened for signs and symptoms of CTD. At 4.8 years of follow-up, 54.7 % patients remained as primary RP, 8.1 % had developed suspected secondary RP, and 37.2 % had developed a definite CTD. Primary RP patients had an earlier onset of RP (mean age of 32.2 years) than those with suspected (mean age 36.5 years, P = .007) or definite secondary RP associated with CTD (mean age of 39.8 years, P = .004). RP beginning before the age of forty was not significantly associated with the development of CTD. Conversely, the appearance of RP after the age of 40 was significantly associated with the development of CTD (P = .00001). Worsening of RP attacks predicted the development of CTD, especially systemic sclerosis (relative risk [RR] of 1.42), scleroderma overlap syndrome (RR of 1.18), and mixed CTD (RR of 1.18). Patients whose onset of RP occurred past 40 years of age and those with worsening RP attacks were at risk for the future development of CTD.
Literature
1.
go back to reference Maricq HR, Weinrich MC, Keil JE, LeRoy EC (1986) Prevalence of Raynaud’s phenomenon in the general population. J Chronic Dis 39:423–427PubMedCrossRef Maricq HR, Weinrich MC, Keil JE, LeRoy EC (1986) Prevalence of Raynaud’s phenomenon in the general population. J Chronic Dis 39:423–427PubMedCrossRef
2.
go back to reference Kallenberg CG (1991) Connective tissue disease in patients presenting with Raynaud’s phenomenon alone. Ann Rheum Dis 50:666–667PubMedCrossRef Kallenberg CG (1991) Connective tissue disease in patients presenting with Raynaud’s phenomenon alone. Ann Rheum Dis 50:666–667PubMedCrossRef
3.
go back to reference Kallenberg CG (1992) Raynaud’s phenomenon as an early sign of connective tissue diseases. Vasa Suppl 34:25–28PubMed Kallenberg CG (1992) Raynaud’s phenomenon as an early sign of connective tissue diseases. Vasa Suppl 34:25–28PubMed
4.
go back to reference Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G et al (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthr Rheum 58:3902–3912CrossRef Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G et al (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthr Rheum 58:3902–3912CrossRef
5.
go back to reference Hirschl M, Hirschl K, Lenz M, Katzenschlager R, Hutter HP, Kundi M (2006) Transition from primary Raynaud’s phenomenon to secondary Raynaud’s phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthr Rheum 54:1974–1981CrossRef Hirschl M, Hirschl K, Lenz M, Katzenschlager R, Hutter HP, Kundi M (2006) Transition from primary Raynaud’s phenomenon to secondary Raynaud’s phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthr Rheum 54:1974–1981CrossRef
6.
go back to reference Ingegnoli F, Boracchi P, Gualtierotti R, Biganzoli EM, Zeni S, Lubatti C et al (2010) Improving outcome prediction of systemic sclerosis from isolated Raynaud’s phenomenon: role of autoantibodies and nailfold capillaroscopy. Rheumatology (Oxford) 49:797–805CrossRef Ingegnoli F, Boracchi P, Gualtierotti R, Biganzoli EM, Zeni S, Lubatti C et al (2010) Improving outcome prediction of systemic sclerosis from isolated Raynaud’s phenomenon: role of autoantibodies and nailfold capillaroscopy. Rheumatology (Oxford) 49:797–805CrossRef
7.
go back to reference Pavlov-Dolijanovic S, Damjanov N, Stojanovic R, Vujasinovic Stupar N, Stanisavljevic D (in press) Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a Follow-up study of 3,029 patients with primary Raynaud’s phenomenon. Rheum Int. doi:10.1007/s00296-011-2109-2 Pavlov-Dolijanovic S, Damjanov N, Stojanovic R, Vujasinovic Stupar N, Stanisavljevic D (in press) Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a Follow-up study of 3,029 patients with primary Raynaud’s phenomenon. Rheum Int. doi:10.​1007/​s00296-011-2109-2
8.
go back to reference Kallenberg CG (1990) Early detection of connective tissue disease in patients with Raynaud’s phenomenon. Rheum Dis Clin N Am 16:11–30 Kallenberg CG (1990) Early detection of connective tissue disease in patients with Raynaud’s phenomenon. Rheum Dis Clin N Am 16:11–30
9.
go back to reference LeRoy EC, Medsger TA Jr (1992) Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol 10:485–488PubMed LeRoy EC, Medsger TA Jr (1992) Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol 10:485–488PubMed
10.
go back to reference LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr et al (1988) Scleroderma (systemic sclerosis): classification, subset and pathogenesis. J Rheumatol 15:202–205PubMed LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr et al (1988) Scleroderma (systemic sclerosis): classification, subset and pathogenesis. J Rheumatol 15:202–205PubMed
11.
go back to reference Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthr Rheum 25:1271–1277CrossRef Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthr Rheum 25:1271–1277CrossRef
12.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum 31:315–324CrossRef Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum 31:315–324CrossRef
13.
go back to reference Alarcon-Segovia D, Cardiel MH (1989) Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 16:328–334PubMed Alarcon-Segovia D, Cardiel MH (1989) Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 16:328–334PubMed
14.
go back to reference Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407PubMedCrossRef Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407PubMedCrossRef
15.
go back to reference Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-Europe Consensus Group. Ann Rheum Dis 61:554–558PubMedCrossRef Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-Europe Consensus Group. Ann Rheum Dis 61:554–558PubMedCrossRef
16.
go back to reference Mosca M, Neri R, Bombardieri S (1999) Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 17:615–620PubMed Mosca M, Neri R, Bombardieri S (1999) Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 17:615–620PubMed
17.
go back to reference Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthr Rheum 42:1309–1311CrossRef Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthr Rheum 42:1309–1311CrossRef
18.
go back to reference Gomariz EM, Del M, Guijo VP, Contreras AE, Villanueva M, Estévez EC (2002) The potential of ESSG spondyloarthropathy classification criteria as a diagnostic aid in rheumatological practice. J Rheumatol 29:326–330PubMed Gomariz EM, Del M, Guijo VP, Contreras AE, Villanueva M, Estévez EC (2002) The potential of ESSG spondyloarthropathy classification criteria as a diagnostic aid in rheumatological practice. J Rheumatol 29:326–330PubMed
19.
go back to reference Balbir-Gurman A, Braun-Moskovici Y (2011) Scleroderma overlap syndrome. Isr Med Assoc J 13:14–20PubMed Balbir-Gurman A, Braun-Moskovici Y (2011) Scleroderma overlap syndrome. Isr Med Assoc J 13:14–20PubMed
20.
go back to reference Campbell G (1994) Advances in statistical methodology for the evaluation of diagnosis and laboratory test. Stat Med 13:499–508PubMedCrossRef Campbell G (1994) Advances in statistical methodology for the evaluation of diagnosis and laboratory test. Stat Med 13:499–508PubMedCrossRef
21.
go back to reference Silman A, Holligan S, Brennan P, Maddison P (1990) Prevalence of symptoms of Raynaud’s phenomenon in general practice. Br Med J 301:590–592CrossRef Silman A, Holligan S, Brennan P, Maddison P (1990) Prevalence of symptoms of Raynaud’s phenomenon in general practice. Br Med J 301:590–592CrossRef
22.
go back to reference Maricq HR, Carpentier PH, Weinrich MC, Keil JE, Palesch Y, Biro C et al (1997) Geographic variation in the prevalence of Raynaud’s phenomenon: a 5 region comparison. J Rheumatol 24:879–889PubMed Maricq HR, Carpentier PH, Weinrich MC, Keil JE, Palesch Y, Biro C et al (1997) Geographic variation in the prevalence of Raynaud’s phenomenon: a 5 region comparison. J Rheumatol 24:879–889PubMed
23.
go back to reference Brand FN, Larson MG, Kannel WB, Mc Guirk JM (1997) The occurrence of Raynaud’s phenomenon in a general population: the Framingham study. Vasc Med 2:296–301PubMed Brand FN, Larson MG, Kannel WB, Mc Guirk JM (1997) The occurrence of Raynaud’s phenomenon in a general population: the Framingham study. Vasc Med 2:296–301PubMed
24.
go back to reference Spencer-Green G (1998) Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 158:595–600PubMedCrossRef Spencer-Green G (1998) Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 158:595–600PubMedCrossRef
25.
go back to reference Porter JM, Bardana EJ Jr, Baur GM, Wesche DH, Andrasch RH, Rosch J (1976) The clinical significance of Raynaud’s syndrome. Surgery 80:756–764PubMed Porter JM, Bardana EJ Jr, Baur GM, Wesche DH, Andrasch RH, Rosch J (1976) The clinical significance of Raynaud’s syndrome. Surgery 80:756–764PubMed
26.
go back to reference Maricq HR, Weinberg AB, LeRoy EC (1982) Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy: a prospective study of patients with Raynaud’s phenomenon. J Rheumatol 9:289–291PubMed Maricq HR, Weinberg AB, LeRoy EC (1982) Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy: a prospective study of patients with Raynaud’s phenomenon. J Rheumatol 9:289–291PubMed
27.
go back to reference Kallenberg CG, Pastoor GW, Wouda AA, The TH (1982) Antinuclear antibodies in patients with Raynaud’s phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis 41:382–387PubMedCrossRef Kallenberg CG, Pastoor GW, Wouda AA, The TH (1982) Antinuclear antibodies in patients with Raynaud’s phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis 41:382–387PubMedCrossRef
28.
go back to reference Ohtsuka T, Tamura T, Yamakage A, Yamazaki S (1998) The predictive value of quantitative nailfold capillary microscopy in patients with undifferentiated connective tissue disease. Br J Dermatol 139:622–629PubMedCrossRef Ohtsuka T, Tamura T, Yamakage A, Yamazaki S (1998) The predictive value of quantitative nailfold capillary microscopy in patients with undifferentiated connective tissue disease. Br J Dermatol 139:622–629PubMedCrossRef
29.
go back to reference Wigley FM, Flavahan NA (1996) Raynaud’s phenomenon. Rheum Dis Clin N Am 22:765–781CrossRef Wigley FM, Flavahan NA (1996) Raynaud’s phenomenon. Rheum Dis Clin N Am 22:765–781CrossRef
30.
go back to reference Ingegnoli F, Boracchi P, Gualtierotti R, Lubatti C, Meani L, Zahalkova L et al (2008) Prognostic model based on nailfold capillaroscopy for identifying Raynaud’s phenomenon patients at high risk for the development of a scleroderma spectrum disorder. PRINCE (Prognostic Index for Nailfold Capillaroscopic Examination). Arthr Rheum 58:2174–2182CrossRef Ingegnoli F, Boracchi P, Gualtierotti R, Lubatti C, Meani L, Zahalkova L et al (2008) Prognostic model based on nailfold capillaroscopy for identifying Raynaud’s phenomenon patients at high risk for the development of a scleroderma spectrum disorder. PRINCE (Prognostic Index for Nailfold Capillaroscopic Examination). Arthr Rheum 58:2174–2182CrossRef
31.
go back to reference Meli M, Gityelmann G, Koppensteiner R, Amann-Vesti BR (2006) Predictive value of nailfold capillaroscopy in patients with Raynaud’s phenomenon. Clin Rheumatol 25:153–158PubMedCrossRef Meli M, Gityelmann G, Koppensteiner R, Amann-Vesti BR (2006) Predictive value of nailfold capillaroscopy in patients with Raynaud’s phenomenon. Clin Rheumatol 25:153–158PubMedCrossRef
Metadata
Title
Late appearance and exacerbation of primary Raynaud’s phenomenon attacks can predict future development of connective tissue disease: a retrospective chart review of 3,035 patients
Authors
Slavica Pavlov-Dolijanovic
Nemanja S. Damjanov
Nada Z. Vujasinovic Stupar
Goran L. Radunovic
Roksanda M. Stojanovic
Dragan Babic
Publication date
01-04-2013
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 4/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2484-3

Other articles of this Issue 4/2013

Rheumatology International 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.